NCT04416750View on ClinicalTrials.gov

Positioning Imatinib for Pulmonary Arterial Hypertension

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Imatinib Mesylate

Treatment with Imatinib

Trial Locations (4)

W12 0HS

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London

CB2 0AY

Royal Papworth Hospital, Royal Papworth Hospital NHS Foundation Trust, Cambridge

SW3 6NP

Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust, London

S10 2JF

Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation, Sheffield

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

Medical Research Council

OTHER_GOV

collaborator

University of Cambridge

OTHER

collaborator

University of Sheffield

OTHER

lead

Imperial College London

OTHER